This site is intended for healthcare professionals

Specialty Hub

In-depth learning materials and relevant resources by areas of interest.
Welcome:
Sign in/Register
Updates in your area
of interest
Articles your peers
are looking at
Bookmarks
saved
Days to your
next event

In this section

Cardiology

Assorted resources on conditions connected to Cardiology.

Dermatology

Latest information on diseases in Dermatology.

Endocrinology

A detailed look at conditions connected to Endocrinology.

Gastroenterology and Hepatology

In-depth material on Gastroenterology and Hepatology.

Haematology

Assorted resources on conditions connected to Haematology.

Infectious Diseases

A detailed look at conditions connected to Infectious Diseases.

Neurology (CNS) and Pain

Learning materials and guidelines on Neurology (CNS) and Pain.

Oncology

A detailed look at conditions connected to Oncology.

Respiratory

In-depth material on Respiratory conditions.

Rheumatology

Latest information on diseases in Rheumatology.

Urology

Learning materials and guidelines on Urology.

Latest news

News
Merck Inc. to acquire Pandion Therapeutics including PT 101 for the potential treatment of ulcerative colitis and other autoimmune diseases.

Merck Inc., and Pandion Therapeutics, Inc. announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash.

1 mins
News
Results from pivotal phase II KarMMa study of idecabtagene vicleucel to treat refractory multiple myeloma were published in NEJM. - bluebird bio + BMS

Results from the pivotal Phase II KarMMa study evaluating the efficacy and safety of bluebird bio, Inc. and Bristol Myers Squibb’s investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, idecabtagene vicleucel (ide-cel; bb2121), in adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, were published in The New England Journal of Medicine.

1 min
News
Pfizer Inc. + BioNTech SE announced that the first participants have been dosed in a global phase II/III study to evaluate the Pfizer-BioNTech COVID-19 vaccine in preventing COVID-19 in pregnant women 18 years of age and older .

Pfizer Inc. and BioNTech SE announced that the first participants have been dosed in a global Phase II/III study to further evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in preventing COVID-19 in healthy pregnant women 18 years of age and older.

1 min
See all news

You may be interested in...
Journal

Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2

Background: 300 mg of intravenous anifrolumab every 4 weeks added to standard-of-care treatment for patients with systemic lupus erythematosus (SLE) reduced disease activity and glucocorticoid requirement in a previous phase 3 trial.

3 mins
Journal

Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials

Chronic activation of the type I interferon (IFN) pathway plays a critical role in systemic lupus erythematosus (SLE) pathogenesis. Anifrolumab is a human monoclonal antibody to the type I IFN receptor subunit 1, which blocks the action of type I IFNs.

1 min
Journal

Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis

Purpose: Accumulative studies showed that tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) was up-regulated in the blood and urine from patients diagnosed with lupus nephritis (LN) and that it might be used as a novel biomarker for active LN. This meta-analysis aimed to determine the diagnostic value of TWEAK in active LN.

1 min